Confluent Shares Rise 0.10% on $1.9B Volume 66th in Daily Market Activity Amid IBM Merger Uncertainty

Market Snapshot

On February 5, 2026, Confluent (CFLT) closed with a 0.10% increase, bringing its share price to $30.42. The stock recorded a trading volume of $1.90 billion, ranking 66th in market activity for the day. This modest gain followed a narrow intraday range, with the stock fluctuating between $30.28 and $30.50. Despite the upward movement, shares remained approximately 2% below the $31-per-share cash offer outlined in Confluent’s pending merger agreement with IBM. The volume surge, driven by merger-arbitrage speculation and regulatory developments, marked a significant increase from the company’s average trading activity.

Key Drivers

The announcement of Confluent’s $11 billion all-cash merger with IBM, disclosed on February 4, 2026, remains the primary catalyst for recent market activity. The transaction, which would see Confluent become a wholly owned subsidiary of IBM, is expected to close by mid-2026 but requires final regulatory approvals and shareholder approval at a special meeting scheduled for February 12. The deal, framed by IBM as a strategic move to build a “smart data platform for enterprise IT, purpose-built for AI,” aligns with broader industry trends in data-streaming and AI infrastructure. Confluent’s CEO, Jay Kreps, has expressed optimism about the potential for integration, though the stock’s limited price movement suggests investor caution ahead of critical upcoming milestones.

Legal and regulatory uncertainties have further shaped market sentiment. On February 4, Confluent filed updated disclosures to address litigation concerns, following 17 demand letters alleging omissions in its proxy statement. While the company has denied the allegations, the supplementary filings reflect heightened scrutiny. Separately, the U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on January 12, removing one hurdle but leaving other regulatory reviews outstanding. These developments underscore the risk of delays or additional legal challenges, which could widen the current 2% discount between the stock price and the $31 offer.

Trading volume surged to 53 million shares on February 4, nearly five times the average of 12 million, as merger-arbitrage traders closely monitored the spread between the stock and the cash offer. This activity intensified ahead of key dates, including the February 11 earnings release and the February 12 shareholder vote. Confluent has opted not to hold an earnings call or issue forward guidance while the IBM deal remains pending, potentially limiting transparency for investors. The stock’s recent range-bound performance—closing at $30.54 on February 2 and $30.45 on February 3—highlights the market’s reluctance to price in significant volatility until these events resolve.

The proximity of the stock price to the $31 offer price has become a focal point for traders. A discount of 58 cents (2%) reflects the perceived risk of a delayed closing or regulatory pushback. If the merger closes on schedule, the discount is expected to narrow, potentially driving short-term gains. Conversely, any delays—whether due to shareholder opposition, regulatory pushback, or unanticipated legal issues—could deepen the discount and erode investor confidence. The February 11 earnings report, though not accompanied by a call, may provide indirect signals about the company’s operational health, influencing the timeline for the transaction.

Looking ahead, the February 12 shareholder vote will be a decisive event. While Confluent’s board has indicated support for the deal, shareholder dissent could prolong the process. Additionally, the broader market’s reaction to IBM’s integration strategy and the competitive landscape for data-streaming platforms may indirectly affect investor sentiment. For now, the stock’s muted movement suggests that investors are adopting a wait-and-see approach, prioritizing risk mitigation over aggressive position-taking until the critical dates pass.